ACHIEVE Ph 2b Trial Advanced with Final Dosing of 3 Patients
“As we progress with Cohort B, there is the potential for an expedited review given these patients’ stage and disease expression,” said Bryan Kobel, CEO of TC BioPharm. “We believe minimal residual disease represents a high opportunity for TCB008 to be extremely impactful. We could see a response indicating high responsiveness in fewer than the currently proposed cohort size. At this trial stage, we are still collating data, due to the regulatory framework, we cannot yet comment on efficacy specifically, but we are encouraged to see patients completing the dosing regimen successfully and without any safety issues. Our immediate clinical focus will be high recruitment on Cohort B in 2025 and completing the Cohort A patient set for data review. We appreciate the hard work of the King’s College Hospital and our fantastic investigator group including Dr. Victoria Potter, and Dr. Emma Nicholson. The recruitment has been exceptional and we look forward to continuing our work with them in 2025.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the